The Author: Dr Gregory King is a Research Leader at The Woolcock Institute of Medical Research, staff specialist and Medical Director of the Respiratory Investigation Unit at the Department of Respiratory Medicine, Royal North Shore Hospital, Conjoint Associate Professor of the Northern and Central Clinical Schools, Sydney Medical School, Sydney University and NH&MRC Practitioner Fellow. He has research interests in airway mechanics and underlying mechanisms of airways disease.
Cutting edge technologies in respiratory research: Lung function testing
Article first published online: 25 JUL 2011
© 2011 The Author. Respirology © 2011 Asian Pacific Society of Respirology
Volume 16, Issue 6, pages 883–890, August 2011
How to Cite
KING, G. G. (2011), Cutting edge technologies in respiratory research: Lung function testing. Respirology, 16: 883–890. doi: 10.1111/j.1440-1843.2011.02013.x
Conflict of interest statement: Between 2006 and 2010, Dr Gregory King has received various travel sponsorships from Boehringer Ingelheim, Pfizer, AstraZeneca and GlaxoSmithKline for travel and accommodation to attend international, local and interstate meetings that include Pharmaceutical Industry sponsored meetings and independent Society Scientific meetings. A proportion of Dr King's research work is conducted at the Woolcock Institute of Medical Research, which receives unrestricted grants from Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline, and which also has current and past consultancy agreements with Pfizer, Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline. Dr King provides consultancy services related to asthma and COPD, which include sitting on advisory boards and providing talks at local and national meetings. His research group receives a proportion of the grants and monies that arise from those companies, as part of a general allocation of those funds for research purposes across all research groups of the Woolcock Institute of Medical Research. Dr King's research group is supported from competitive grants arising from local research foundations, the National Health & Medical Research Council of Australia, Cooperative Research Centre for Asthma and Airways and The Australian Lung Foundation.
- Issue published online: 25 JUL 2011
- Article first published online: 25 JUL 2011
- Accepted manuscript online: 27 JUN 2011 11:56AM EST
- Received 17 April 2011; invited to revise 26 May 2011; revised 15 June 2011; accepted 16 June 2011.
- complex lung function testing;
- lung and airway mechanics;
- obstructive airways disease;
- respiratory structure and function
Pulmonary function testing is part of routine clinical practice in respiratory medicine. It is based around spirometry, which will remain the central measurement of lung function given its prognostic significance and its integral role in defining severity of airways disease. However, there is an increasing body of evidence from studies using new methods of lung function measurement which are providing new insights into pathophysiology of disease. This body of data is forming a basis for their future clinical role, once the economics of producing the relevant devices becomes attractive. The forced oscillation technique and multiple breath nitrogen washout are currently the most commonly used of the newer lung function techniques, which are refinements of long-established techniques. Optical coherence tomography, optical reflection, electrical impedance and vibration response imaging have arisen by development of novel devices. The recent use of these techniques is reviewed.